Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions
Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...
Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...
AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion
China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...
AstraZeneca and Merck’s Lynparza Receives New Approval in China
UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...
Shandong Luoxin Partners with Shanghai Pharma for Strategic Services
China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with...
NHSA Releases Guide on Volume-Based Procurement Drug Equivalents
The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...
Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...
Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine
Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...
Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center
German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...
METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program
Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...
Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme
Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...
Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare
Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...
Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...
Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2
Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
Koutech Robotics Secures Series A Funding for Surgical Innovation
China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...